Company intelligence / Profile preview
Mwyngil Therapeutics
San Diego, California, United Statesmwyngil.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
No clinical results reported; lead NLRP3 small molecule inhibitor BT-409 demonstrated brain penetration and promising safety/pharmacokinetics in preclinical neuroinflammation models
- Therapeutic areas
- CardiovascularImmunologyEndocrinologyRheumatologyGastroenterologyNeurologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
i2020 Accelerator (Torrey Pines Investment, OrbiMed)Brenig Therapeutics (asset buyer)
Beyond the preview
Go deeper on Mwyngil Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mwyngil Therapeutics.